Amentoflavone vs Apigenin

Amentoflavone wins for strong CYP3A4 inhibition (making it a top-tier stim-potentiator and PK amplifier), higher potency at the benzodiazepine GABA_A site (for edge-off, non-sedating anxiolysis), and unique activity blocking pancreatic lipase (minor fat absorption modulation).

Apigenin wins for overall safety profile, broader mechanistic coverage (GABAergic, aromatase inhibition, and CD38 antagonism for NAD+ preservation), easier sourcing as a standalone powder, and better real-world oral bioavailability. It shines for sleep, NAD+ longevity protocols, and mild estrogen management—without the CYP interaction caveats.

Pick Amentoflavone if:

• The protocol stacks potent stimulants or thermogenics and needs CYP3A4 inhibition to extend their effects.
• The evening stack calls for a strong anxiolytic GABAergic modulator that won't leave users sedated.
• The research aim is direct PK amplification of co-administered lab actives.
• Users want one of the most potent plant-sourced benzodiazepine-site ligands documented.
• Lipase inhibition and minor gut fat-absorption effects are a secondary goal.

Pick Apigenin if:

• The priority is sleep-onset or sleep quality support in a GABAergic/relaxation stack.
• CD38 inhibition (NAD+ preservation) is part of a longevity or anti-aging stack, especially alongside NMN/NAD+ boosters.
• Soft aromatase inhibition is needed for estrogen modulation on-cycle or in PCT without pharm-grade prescription AI side effects.
• Safety, tolerability, and easy, cheap sourcing are high priorities.
• The protocol requires nightly use over a long-term window without CYP3A4 interaction risks.